Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the objective response rates (ORR) for 150 mg and 300 mg/day of vandetanib in patients with advanced & progressive MTC. ORR = % of patients with a best response of complete or partial response (CR/PR) as per RECIST Version1.1
Critère d'inclusion
- Unresectable locally advanced or metastatic medullary thyroid cancer